Back to top
more

Bristol Myers Squibb (BMY)

(Delayed Data from NYSE)

$45.95 USD

45.95
9,987,365

+0.59 (1.30%)

Updated Aug 8, 2025 04:00 PM ET

After-Market: $45.64 -0.31 (-0.67%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value D Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (147 out of 244)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

New York-based Bristol-Myers Squibb is a one of the leading global specialty bio-pharmaceutical companies focused on the development of treatments targeting serious diseases. Backed by its blockbuster immune-oncology drug, Opdivo, Bristol-Myers has a strong oncology portfolio, consisting of other drugs like Revlimid, Sprycel, Yervoy and Empliciti. Beyond oncology, the company has important immunology and cardiovascular drugs like Orencia and Eliquis, which diversify its portfolio. Notably, in the cardiovascular space, Eliquis is now the global leading oral anti-coagulant drug. The company continues to experience growth in both the Eliquis brand and the market, while also advancing its Factor XIa inhibitor program..

Zacks Equity Research

Exelixis (EXEL) Q1 Earnings & Sales Top on Cabometyx Strength

by Zacks Equity Research

Exelixis (EXEL) posted a strong performance in the first-quarter as lead drug Cabometyx made further inroads in the RCC market.

    Zacks Equity Research

    The Zacks Analyst Blog Highlights: Amazon, Bristol-Myers, Time Warner, Northrop Grumman and Honda

    by Zacks Equity Research

    The Zacks Analyst Blog Highlights: Amazon, Bristol-Myers, Time Warner, Northrop Grumman and Honda

      Zacks Equity Research

      Incyte (INCY) Incurs Loss in Q1, Revenues Miss Estimates

      by Zacks Equity Research

      Incyte (INCY) reported disappointing results for the first quarter wherein the company reported a loss against expectation of earnings and sales too missed estimates.

        Zacks Equity Research

        Is a Beat in the Cards for Exelixis (EXEL) in Q1 Earnings?

        by Zacks Equity Research

        Exelixis is likely to beat on earnings when it reports first-quarter results (May 2) driven by strong growth of Cabometyx sales.

          Zacks Equity Research

          Drug Stocks Q1 Earnings to Watch on May 1: PFE, MRK & More

          by Zacks Equity Research

          Four pharma/biotech companies are set to release earnings report on May 1. Let's take a look into how the companies are placed ahead of the upcoming results.

            Zacks Equity Research

            AVEO Pharmaceuticals (AVEO) Q1 Earnings: What's in Store?

            by Zacks Equity Research

            AVEO Pharmaceuticals' (AVEO) first drug, Fotivda for the first-line treatment of RCC is likely to have a favorable impact on first-quarter results.

              Zacks Equity Research

              Seattle Genetics (SGEN) Q1 Earnings Lag Estimates, Sales Top

              by Zacks Equity Research

              Seattle Genetics (SGEN) first-quarter earnings miss estimates while sales beat the same.

                Zacks Equity Research

                Bristol-Myers (BMY) Beats on Q1 Earnings, Opdivo Impresses

                by Zacks Equity Research

                Bristol-Myers (BMY) beats estimates on both counts in the first quarter. Eliquis and Opdivo record solid sales.

                  Zacks Equity Research

                  Bristol-Myers (BMY) Q1 Earnings Beat Estimates

                  by Zacks Equity Research

                  Bristol-Myers (BMY) beat estimates on both counts.

                    Zacks Equity Research

                    Drug Stock Q1 Earnings Due on Apr 26: ABBV, ALXN, BMY & VRTX

                    by Zacks Equity Research

                    Four pharma/biotech companies are set to release earnings report on Apr 26. Let's take a look into how the companies are placed ahead of the upcoming results.

                      Zacks Equity Research

                      Why Bristol-Myers (BMY) Might Surprise This Earnings Season

                      by Zacks Equity Research

                      Bristol-Myers (BMY) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

                        Zacks Equity Research

                        Will Pfizer's (PFE) Earnings Beat Estimates Again in Q1?

                        by Zacks Equity Research

                        While Pfizer's (PFE) new drugs like Ibrance and Xeljanz are likely to drive Q1 sales, genericization of key drugs and supply shortages in legacy Hospira products will hurt the same.

                          Zacks Equity Research

                          What's in the Cards for Merck (MRK) This Earnings Season?

                          by Zacks Equity Research

                          Merck's (MRK) new products like Keytruda and Bridion are likely to drive first-quarter sales. However, headwinds remain in the form genericization of key drugs and increasing competition.

                            Zacks Equity Research

                            Is a Beat in the Cards for AbbVie (ABBV) in Q1 Earnings?

                            by Zacks Equity Research

                            Impressive sales rise of AbbVie's (ABBV) key drugs, Humira and Imbruvica, might lead the company to an earnings beat in Q1.

                              Zacks Equity Research

                              Can Allergan (AGN) Keep the Earnings Streak Alive in Q1?

                              by Zacks Equity Research

                              While Allergan's (AGN) Q1 sales are likely to be driven by new as well as established products like Botox and international growth, generic competition for some key products is expected to hurt sales.

                                Sweta Killa headshot

                                Q1 Earnings Surprise Well in Cards: Healthcare ETFs to Buy

                                by Sweta Killa

                                Let's dig into the earnings picture of the companies that would drive the performance of the popular health care ETFs in the coming days.

                                  Zacks Equity Research

                                  FDA Nods to AstraZeneca's Tagrisso for First-Line NSCLC (revised)

                                  by Zacks Equity Research

                                  Tagrisso is approved in the United States, European Union, Japan and China as second-line treatment for patients with advanced NSCLC.

                                    Zacks Equity Research

                                    Is a Beat in Store for Bristol-Myers (BMY) in Q1 Earnings?

                                    by Zacks Equity Research

                                    Bristol-Myers (BMY) is scheduled to report Q1 earnings on Apr 26.

                                      Zacks Equity Research

                                      Pharma Stock Roundup: NVS, JNJ Q1 Sales & Earnings Top, MRK & BMY Active at AACR

                                      by Zacks Equity Research

                                      Novartis (NVS) and J&J (JNJ) deliver strong Q1 results. Merck (MRK) and Bristol Myers (BMY) present lung cancer data at AACR.

                                        Zacks Equity Research

                                        Bristol-Myers' Opdivo Gets Priority Review for Lung Cancer

                                        by Zacks Equity Research

                                        The FDA accepts Bristol-Myers Squibb's (BMY) supplemental Biologics License Application and grants priority review for the label expansion of Opdivo to treat patients with small cell lung cancer.

                                          Zacks Equity Research

                                          FDA Nods to AstraZeneca's Tagrisso for First-Line NSCLC

                                          by Zacks Equity Research

                                          AstraZeneca (AZN) wins the FDA approval for the label expansion of its marketed drug, Tagrisso, for first-line treatment of adult patients with locally-advanced or metastatic NSCLC.

                                            Zacks Equity Research

                                            Calithera's Kidney Cancer Candidate Gets Fast Track Status

                                            by Zacks Equity Research

                                            Calithera Biosciences' (CALA) lead pipeline candidate, CB-839, gets fast track status in the United States for the treatment of kidney cancer.

                                              Zacks Equity Research

                                              Merck's Keytruda Betters Survival in Lung Cancer Combo Study

                                              by Zacks Equity Research

                                              Merck (MRK) releases complete data from a phase III study showing Keytruda in combination with Lilly's Alimta and platinum chemotherapy reducing death risk by half compared with only chemotherapy.

                                                Zacks Equity Research

                                                Bristol-Myers (BMY) Down as Merck NSCLC Study Fares Better

                                                by Zacks Equity Research

                                                Bristol-Myers (BMY) stock declined as the company reported encouraging results from its NSCLC study but competitor Merck scored better in the same regard.

                                                  Zacks Equity Research

                                                  Celldex's Phase II Breast Cancer Study Fails, Shares Plunge

                                                  by Zacks Equity Research

                                                  Celldex Therapeutics' (CLDX) glembatumumab vedotin fails to meet primary endpoint in phase IIb METRIC study in metastatic breast cancer.